business
Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?
Key takeaways
- Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?
- Despite MRNA's 130% YTD surge, Wall Street's consensus target of $43 sits well below the current price, with heavy insider net-selling adding caution.
- Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Merck didn't make the cut.
Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer? David Moadel Fri, June 26, 2026 at 11:01 PM GMT+7 4 min read MRNA MRK PFE NVDA Quick Read MRNA surged 14%, dwarfing the 2% gains of MRK and PFE, driven by an FDA flu vaccine endorsement and a blowout Q1 revenue beat.
Despite MRNA's 130% YTD surge, Wall Street's consensus target of $43 sits well below the current price, with heavy insider net-selling adding caution.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Merck didn't make the cut. Grab the names FREE today.
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop